Latest Breaking News On - Neuroscience thematic research - Page 1 : comparemela.com

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will.

Richard hargreavesProthena corporationBristol myers squibbExchange commissionCompany on twitter prothenacorpDrug administrationGene kinneyChief executive officerSenior vice presidentNeuroscience thematic researchQuarterly report

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will

Richard hargreavesMichael bachnerMark johnsonCorporate communicationsBristol myers squibbCompany on twitter prothenacorpDrug administrationExchange commissionProthena corporationGene kinneyChief executive officerSenior vice presidentNeuroscience thematic researchQuarterly reportSenior directorVice president

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau

Prothena to receive $55 million from Bristol Myers Squibb for exclusive worldwide license to PRX005, building on exclusive U.S. license which was optioned in June 2021Bristol Myers Squibb will be responsible for development, manufacturing, and commercialization going forward DUBLIN (BUSINESS WIRE) $PRTA #prothena-.

Michael bachnerRichard hargreavesBristol myers squibbProthena corporationCorporate communicationsCompany on twitter prothenacorpExchange commissionMyers squibbGene kinneyChief executive officerSenior vice presidentNeuroscience thematic researchQuarterly reportInvestor contactSenior director

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Prothena to receive $55 million from Bristol Myers Squibb for exclusive worldwide license to PRX005, building on exclusive U.S. license which was optioned in June 2021 Bristol Myers Squibb will be responsible for development, manufacturing, and commercialization going forward

Richard hargreavesBristol myers squibbCompany on twitter prothenacorpProthena corporationExchange commissionGene kinneyChief executive officerSenior vice presidentNeuroscience thematic researchQuarterly report

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Michael bachnerRichard hargreavesProthena corporationCompany on twitter prothenacorpCorporate communicationsExchange commissionBristol myers squibbMyers squibbGene kinneyChief executive officerSenior vice presidentNeuroscience thematic researchQuarterly reportInvestor contactSenior directorIhre watchlist